NuVasive to Participate in Canaccord Genuity 42nd Annual Growth Conference
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, announced that CFO Matt Harbaugh will speak at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 11, 2022, at 1:30 p.m. ET. A live webcast of the presentation will be available on the company's Investor Relations page, with a replay accessible for 30 days post-event. NuVasive focuses on minimally invasive surgical solutions, boasting over $1 billion in net sales and operating in more than 50 countries, catering to surgeons and hospitals.
- None.
- None.
SAN DIEGO, July 28, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Financial Officer Matt Harbaugh will participate in the Canaccord Genuity 42nd Annual Growth Conference in Boston on Thursday, August 11, 2022 at 1:30 p.m. ET.
A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, a replay of the presentation will remain available on the website for 30 days.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than
Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-to-participate-in-canaccord-genuity-42nd-annual-growth-conference-301594951.html
SOURCE NuVasive, Inc.
FAQ
What event will NuVasive participate in on August 11, 2022?
Who will represent NuVasive at the Canaccord Genuity conference?
Where can I watch the NuVasive presentation live?
How long will the NuVasive conference presentation replay be available?
What is NuVasive's primary focus in the medical field?
